SUMMARY The costs and benefits of early thrombolytic treatment with intracoronary streptokinase in acute myocardial infarction were compared in a randomised trial. All hospital admissions were recorded and the functional class was assessed at visits to the outpatient clinic during a 12 month follow up of 269 patients allocated to thrombolytic treatment and of 264 allocated to conventional treatment. Mean survival during the first year was calculated for patients with inferior and with anterior infarction and adjusted for impaired quality of life in cases where there were symptoms or hospital admission. In patients with inferior infarction mean survival was 337 days (out of a total follow up of 365 days) for patients allocated to thrombolytic treatment and 327 days for controls. Quality adjusted survival was seven days longer in the thrombolysis group (307 vs 300 days in controls). In patients with anterior infarction mean survival was significantly longer (35 days) in the thrombolysis group than in the control group as was quality adjusted survival (38 days) (304 vs 266 days in controls). The gain in life expectancy with thrombolytic treatment was 0 7 years for patients with inferior infarction, 2-4 years for patients with anterior infarction, and 3 6 years for the subset of patients with large anterior infarction who were admitted within two hours of the onset of symptoms. The costs of medical treatment, including medication, hospital stay, cardiac catheterisation, coronary angioplasty, and bypass surgery, in the first year follow up were higher in patients allocated to thrombolytic treatment (an additional cost ofDfl 7000 in inferior and Dfl 9000 in anterior infarction (L1 Dfl 3 3)) than in conventionally treated patients. The additional costs per year of life gained were Dfl 10 000 in inferior infarction, Dfl 3 800 in anterior infarction, and only Dfl 1 900 in patients with large anterior infarction admitted within two hours of onset of symptoms.
528 often in patients allocated to thrombolytic treatment than in the control group."2 The improved survival after early thrombolytic treatment on one hand and the higher incidence of non-fatal complications in these patients make it difficult to assess the true value of thrombolytic treatment in acute myocardial infarction. To obtain a complete picture of total mortality and morbidity the functional status of each patient was recorded at regular intervals during one year follow up. Also the total medical costs were recorded for each patient. From these data mean survival was calculated and adjusted for impaired quality of life when there were symptoms or hospital admission. The additional costs of thrombolytic treatment per year of life gained were also calculated.
Patients and methods
Five hundred and thirty three patients entered the trial as described in an earlier report.' Patients were eligible for the trial ifthey were admitted to one ofthe five participating coronary care units within four hours of the onset of chest pain with electrocardiographic signs that were typical of myocardial infarction. Two hundred and sixty four patients were allocated to conventional treatment and 269 to thrombolytic treatment. Of the latter patients, 152 were allocated to intracoronary streptokinase and 1 17 to intracoronary streptokinase preceded by intravenous streptokinase. Patients allocated to thrombolytic treatment were asked for their informed consent. Patients who refused consent or patients in whom thrombolytic treatment was withheld for other reasons received conventional treatment, but were included in the analysis on the basis of the intention to treat.7 Acute coronary angiography was performed in 234 patients allocated to thrombolytic treatment. If the infarct related coronary artery appeared to be occluded, intracoronary streptokinase (usually 250 000 U) was given. In the second part ofthe study intravenous streptokinase (500 000 U) was given before angiography to reduce treatment delay. In 46 patients with severe residual stenosis of the infarct related coronary artery, coronary angioplasty was attempted as part of the recanalisation procedure. After catheterisation patients allocated to thrombolytic treatment had the same treatment protocol as the control group.' The location of the infarct was defined as anterior if there was ST segment elevation in leads V1 to V4 and as inferior if there was ST segment elevation in leads II, III, and aVF. When there was ST segment elevation in leads I, aVL, V5 and V6, the infarct was defined as anterior, unless ST segment elevation was also present in leads II, III, and aVF or ST segment depression was present in leads VI to V4. In the latter case the infarct was Vermeer, Simoons, de Zwaan, et al defined as inferior. The ZST on the electrocardiogram was defined for anterior infarcts as the sum of ST segment elevation in leads I, aVL, and Vi to V6 and that for inferior infarcts was defined as the sum of ST segment elevation in leads I, II, III, aVL, aVF, V5 and V6, and ST segment depression in leads Vl to V4.6
All patients were followed at the outpatient clinic for at least a year after admission. The following data were recorded: (a) functional class (New York Heart Association) on the day of each visit to the outpatient clinic8; (b) all hospital admissions, including day of admission, day of discharge, and reason for admission; (c) functional class before hospital admission and functional class at discharge; and (d) day and cause ofdeath and functional class before death (if a patient died).
From these data the functional state ofeach patient was defined every week as the lowest of mutually exclusive classifications: class I (New York Heart Association criteria), not in hospital; class II, not in hospital; class III, not in hospital; class IV, not in hospital; in hospital; or dead.
Functional class was assumed to have changed halfway between two subsequent visits to the outpatient clinic unless known otherwise. The mean number of days spent in each category was calculated for all patients. Mean survival was calculated for each group of patients as the mean time between admission to the study and death or the end of follow up (one year). Survival was adjusted for impaired quality of life according to the number of days spent in class II-IV or in hospital, as described in the results.9 Life expectancy was estimated by the "DEALE" method. 0" The mortality rate was assumed to be 6% per year for patients alive at the end offollow up. Mean life expectancy was calculated for subsets ofpatients in both treatment groups as the interval from admission to the study to death for those who died during follow up and as 16-7 years (mean survival at a mortality rate of6% per year) plus the duration of follow up for those who were alive at the end of follow up.
The costs of medical treatment the first year after acute myocardial infarction were calculated, taking into account the number of days in hospital, the increased costs for stay in a coronary care unit or surgical intensive care unit, costs of acute coronary angiography including thrombolytic treatment with or without coronary angioplasty, costs of elective coronary angiography, elective coronary angioplasty, bypass surgery, and medication as prescribed at discharge or at the outpatient clinic. The costs of medication were based on average dosages of antiarrhythmic drugs, platelet inhibitors, f blockers, cal- Table 2 Hospital admissions, hospital stay, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, and cardiac catheterisations in all patients, in patients with inferior and anterior infarction, and in the subgroup of patients with anterior infarction and extensive myocardial ischaemia admitted to the hospital within two hours of the onset of symptoms (see results)
Anterior infarction ZST> 1-2mV TIhe benefits of thrombolytic treatment were most clear cut in patients with anterior infarction-an observation that accords with the results of the GISSI trial.'7 The site of the infarct was based on electrocardiographic criteria, which were available shortly after hospital admission. Angiographic data were not used to determine the location of the infarction. Patients in the thrombolysis group in whom the infarct related obstruction was in the circumflex artery (as assessed by acute angiography) had electrocardiographic signs of anterior infarction in approximately 40% of the cases and of inferior infarction in 60%. In this analysis all hospitals admissions were recorded and functional class was defined for each patient at regular intervals during one year follow up according to the method proposed by Olsson et al. "8 This enabled us to compare differences in mortality and morbidity between the two treatment groups. Although the assessment of impairment in the quality of life when angina pectoris-or heart failure occur is dependent on the patient's opinion, the quality of life can be measured objectively by the patient's ability to carry on normal activity9 as estimated by the Karnofsky Performance Status Scale. It is evident that in patients with anterior infarction thrombolytic treatment improved both life expectancy and quality of life, while the beneficial effects of thrombolytic treatment in inferior infarction remained small. These conclusions are independent ofthe method ofquality adjustment, and remain unchanged when other quality adjustment factors are used. The total duration ofhospital stay was the same in both treatment groups. However, admissions in the thrombolysis group were more often related to ischaemia (because of reinfarction and for additional revascularisation procedures such as coronary angioplasty or bypass surgery), whereas in the control group more admissions were the result of heart failure. This confirms that left ventricular function was more impaired in conventionally treated patients. The data shows that in both treatment groups most patients were free of symptoms during a one year follow up. The proportion of patients with symptoms was larger in the control group (33%) than in the thrombolysis group (22%) for patients with anterior infarction. Thus thrombolytic treatment improved survival and the quality oflife in this group of patients. I-t is not clear why thrombolytic treatment was less effective in patients with inferior infarction. A possible explanation could be the higher reinfarction rate seen in these patients which abolishes the initially beneficial effects of thrombolytic treatment (table 1) .
In the calculation of mean life expectancy a mortality rate of 6% per year was assumed for patients in both treatment groups. Sensitivity analysis indicated that the differences in mean life expectancy between the two treatment groups (table   5) Vermeer, Simoons, de Zwaan, et al administration of thrombolytic treatment was balanced by the lower incidence of complications in the coronary care unit.'9 This is why we used the average costs for stay on the coronary care unit.
Total costs per patient during one year follow up appeared to be higher after thrombolytic treatment, mainly because of the costs of acute angiography and subsequent coronary angioplasty or bypass surgery. None the less, the cost benefit analysis shows that intracoronary thrombolytic treatment with streptokinase is cheaper than other established medical treatments. For example the cost of a one year increase in quality adjusted life expectancy after bypass surgery as calculated by Weinstein and Stason varied from Dfl 20 000 to Dfl 75 00020 while the costs for treatment of moderate diastolic hypertension were Dfl 30 000 to Dfl 90 000 per year of life gained (Al Dfl 3.3).21 The cost benefit ratio of thrombolytic treatment is good because it requires only one intervention during hospital admission and has considerable beneficial effects, especially in patients with a larger anterior infarction. The treatment can thus be limited to a well defined and easily recognised group of patients, while hypertension treatment must be given to large numbers of patients for a long time in order to prevent or delay quite a small number of cardiovascular events.
A disadvantage of intracoronary thrombolytic treatment is the need for angiography during the acute stage. We included the costs of equipment and stafffor a 24 hour angiography service in the analysis. We do not know how the cost benefit ratios of intracoronary thrombolysis and intravenous thrombolysis compare. Intravenous administration of streptokinase is initially less expensive, but also considerably less effective than intracoronary treatment in achieving patency, in salvage of myocardial function,22 and in reducing mortality. ' 
